Objective: To assess the efficacy and safety profile of docetaxel, as a single agent, in the treatment of elderly patients with advanced breast cancer. Methods: Twenty-eight patients, with a median ...

Customizing Cisplatin Based on Quantitative Excision Repair Cross-Complementing 1 mRNA Expression: A Phase III Trial in Non–Small-Cell Lung Cancer In this open-label phase II clinical trial, the ...

Dec. 4, 2003 (San Antonio) — Docetaxel (Taxotere) produced better overall survival and longer time to progression than paclitaxel (Taxol) in a randomized head-to-head trial of the two taxanes widely ...

Patients with prostate cancer who receive docetaxel with standard-of-care treatment may have a reduced risk of death and an improved prognosis, according to a recent study. Patients with prostate ...

Survival curves for men treated with and without add-on docetaxel converged with longer follow-up. Based on 10 years of trial follow-up data, docetaxel should not be used to treat high-risk localized ...

Plinabulin at 30 mg / m2 on Days 1 and 8 Keytruda at 200 mg on Day 1 Docetaxel at 75 mg / m² on Day 1 “While PD-1 / PD-L1 inhibitors have significantly advanced cancer treatment, patients still ...

(San Diego, Calif.--September 10, 2024, 10:35 a.m. PCT) A phase 3 study comparing tusamitamab ravtansine with docetaxel in patients with advanced non-squamous non-small cell lung cancer (NSCLC) ...